Global oncology spending is projected to reach US$409bn by 2028E, up from US$223bn in 2023A at a 5yr CAGR of 11.5-14.5% from 2024-2028 (IQVIA, 2024). This growth is in part driven by US spending, which has increased to $99bn in 2023A up from $65bn in 2019A - the US makes up ~45% of global oncology spending.

11 Jul 2024
ACF Insight - Innovations in Oncology - the Future of Cancer Treatment11072024

Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
ACF Insight - Innovations in Oncology - the Future of Cancer Treatment11072024
GILEAD SCIENCES (GILD:NYSE), 0 | Gilead Sciences, Inc. (GILD:NAS), 0 | Bristol-Myers Squibb Co (BMY:NYSE), 0 | Bristol-Myers Squibb Company (BMY:NYS), 0 | Novartis AG (NOT:ETR), 0 | IceCure Medical Ltd. (ICCM:NAS), 0
- Published:
11 Jul 2024 -
Author:
Research Team ACF -
Pages:
5 -
Global oncology spending is projected to reach US$409bn by 2028E, up from US$223bn in 2023A at a 5yr CAGR of 11.5-14.5% from 2024-2028 (IQVIA, 2024). This growth is in part driven by US spending, which has increased to $99bn in 2023A up from $65bn in 2019A - the US makes up ~45% of global oncology spending.